Goodman, Pro Medicus and ResMed FY26 Results: Growth Drivers and FY27 Outlook

Sonal Goyal

21 October 2026 11:06 PM AEDT

Goodman, Pro Medicus and ResMed FY26 Results: Growth Drivers and FY27 Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Goodman Group (ASX:GMG) reported operating profit of $2,675 million, up 15.7%, with data centres 78% of development work in progress.
Pro Medicus (ASX:PME) said NPAT grew more than 32% in constant currency and described its second-biggest year for new contracts.
ResMed (ASX:RMD) reported FY2026 Revenue of US$5.7 billion, up 10%, and non-GAAP EPS of US$11.17, up 17%.

Data centre developers, medical imaging software providers and sleep therapy device makers have all reported results tied to technology and healthcare demand. This article reviews the latest results of Goodman Group (ASX:GMG), Pro Medicus Limited (ASX:PME) and ResMed Inc. (ASX:RMD), based on their company announcements.

Sector context

These companies are exposed to data centre and property development cycles, hospital and healthcare technology budgets, currency translation and, for ResMed, medical device Demand and reimbursement. The releases refer to artificial intelligence, cloud demand and the strength of the Australian dollar.

Goodman Group (ASX:GMG)

Goodman reported FY26 results on 20 August 2026. Operating profit was $2,674.5 million, up 15.7%, operating Earnings per security were 129.9 cents, up 10.1%, and statutory profit was $2,778.7 million. The distribution was 30.0 cents per security, gearing was 6.5%, and net tangible assets per security were $11.79, up 7%. The total portfolio was $89.0 billion, with occupancy of 95.6% and like-for-like net property income growth of 4.0%.

Work in progress was $19.7 billion across 50 projects in 12 countries, with data centres making up 78% and a forecast Yield on cost of 8.2%. The global power bank rose to 6.4 GW across 16 major cities, and the group is targeting FY27 operating earnings per security growth of 9%.

Pro Medicus Limited (ASX:PME)

Pro Medicus published a question-and-answer interview with its CEO on 18 August 2026 about its full-year results. The company said it increased revenue and profit after tax on a constant currency basis, with NPAT up more than 32% in constant currency, and that it had its second-biggest year for new contracts after FY25, six major renewals and its busiest year for implementations, many late in the second half.

Currency translation reduced revenue by just under $12 million and NPAT by $9.8 million, as the Australian dollar rose over the past six months. The company said implementations did not contribute materially to FY26 revenue but will provide a step-up in FY27 from a full 12 months of revenue. It also discussed AI, cardiology and a $10 million Investment in 4D Medical and a further $10 million into Echo IQ.

ResMed Inc. (ASX:RMD)

ResMed announced fourth quarter and fiscal year 2026 results on 6 August 2026, in US dollars. Fiscal year revenue rose 10% to US$5.7 billion (8% in constant currency), with GAAP gross Margin of 61.1% and non-GAAP gross margin of 62.4%. GAAP Operating Margin was 33.4%, GAAP diluted EPS was US$10.43 and non-GAAP diluted EPS was US$11.17, up 17%. Operating Cash Flow was US$1.8 billion and free cash flow was US$1.6 billion.

Fourth quarter revenue rose 9% to a record US$1.5 billion. ResMed guided to more than US$1.85 billion of Capital returned through repurchases and dividends in FY2027, announced a 10% increase in its quarterly Dividend to US$0.66, agreed to sell its MatrixCare Business and completed the Acquisition of Noctrix Health.

What the three announcements show

Goodman’s results highlight data centre development, Pro Medicus’ interview highlights contract wins and currency effects, and ResMed’s release highlights margins and capital returns. The Pro Medicus document is an interview rather than a formal results release, so it gives fewer financial figures than the other two.

FAQs

Q: What was Goodman Group’s (ASX:GMG) FY26 operating profit?

A:$2,674.5 million, up 15.7%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.